

# Appendixes

## Appendix A: Cervical cancer—symptoms, detection and treatment

Cervical cancer affects the cells of the cervix, which is the lower part of the womb (uterus) as it joins the inner end of the vagina. Like other cancers, cervical cancer is a disease where normal cells change, begin to multiply out of control, and form a growth or tumour. The cancer may arise from the squamous cells at the transformation zone where the squamous cells on the outside of the cervix join the columnar cells in the lining of the cervical canal (squamous cell carcinoma) or from the cells in the cervical canal (adenocarcinoma). Over two-thirds of cervical cancers are squamous cell carcinomas, which are most easily detected on the Pap smear, and about 20% are adenocarcinomas. If not detected early, the tumour can invade local tissue and spread (metastasise) to other parts of the body. The main symptoms of cervical cancer are unusual bleeding from the vagina, and very rarely an unusual vaginal discharge. However, these symptoms are quite common and are usually not due to cancer.

A cervical cancer may take 10 or more years to develop, but before this the cells may show pre-cancerous changes. These early changes can be detected by a Pap smear (described in more detail below), and if they are promptly treated, cervical cancer can be prevented. The National Health and Medical Research Council recently approved a revised classification system of the Australian Modified Bethesda System (2004) which will be used to classify data collected from July 2006 onwards; however the data in this report have been collated using the previous classification system in which these pre-cancerous lesions has two levels of severity, low-grade epithelial abnormalities (LGEA) and high-grade epithelial abnormalities (HGEA). An earlier classification described various grades of cervical intra-epithelial neoplasia (CIN). Low-grade abnormalities include minor changes in squamous cells and CIN 1, and high-grade abnormalities include CIN 2, CIN 3, squamous carcinoma-in-situ, adenocarcinoma-in-situ and invasive carcinoma (squamous or adenocarcinoma).

The Pap smear is the most common way to detect pre-cancerous changes, which rarely cause any symptoms. The test involves a doctor or nurse practitioner inserting a speculum into the vagina and gently scraping the surface of the cervix. This process collects cells that are transferred onto a slide or into a special liquid, which is then sent to a pathology laboratory for assessment. Pap smears are offered by general practitioners, gynaecologists, family planning clinics, women's health centres, hospital outpatient clinics and, in some circumstances, specially trained nurses.

If the Pap smear shows an abnormality, the woman may be advised to have a repeat smear if the abnormality is low-grade or she may be advised to have a colposcopy. With colposcopy, a doctor is able to look directly at the cervix under magnification using an instrument called a colposcope. Using a special stain the doctor can highlight any suspicious area, which may be pre-cancerous or cancerous. The doctor will then take a tissue sample (a biopsy) of the suspicious area for further examination by a pathologist.

Pre-cancerous changes can be easily and effectively be treated to prevent the progression to cervical cancer. The type of treatment depends on whether the change observed is low or

high grade, the woman's age and general health, whether she wants to have children, and on her preferences.

There is a range of treatments for pre-cancerous changes, including laser treatment, loop excision (LLETZ), cryosurgery (cold coagulation), electrodiathermy, or cone biopsy, (either by laser or by scalpel). In a small number of instances, a hysterectomy may be necessary.

For invasive cancer, a cone biopsy or hysterectomy is generally performed. If the cancer cells are detected on the surface of the cervix only, it may be treated by a cone biopsy. If it has invaded deeper into the cervix, a hysterectomy is generally performed. In advanced cases, a radical hysterectomy is needed to remove the cervix and uterus along with a margin of tissue around the cervix and lymph nodes from the pelvis. Radiotherapy is sometimes used as well as surgery, and for more advanced cases it may be used on its own.

## Appendix B: Data sources and limitations

All data used in this report are based on calendar years. Data are derived from multiple sources and are summarised below.

**Table B1: Cervical cancer screening indicators data sources**

Indicator	Description	Data source
1	Participation rate for cervical cancer screening	National Cervical Screening Program
2	Early re-screening	National Cervical Screening Program
3	Low-grade abnormality detection	National Cervical Screening Program
4	High-grade abnormality detection	National Cervical Screening Program
5.1	Incidence of micro-invasive cervical cancer National Cancer Statistics Clearing House (ICD10 C53)	National Cancer Statistics Clearing House
5.2	Incidence of squamous, adenocarcinoma, adeno-squamous and other cervical cancer (ICD10 C53)	National Cancer Statistics Clearing House
5.3	Incidence by location (ICD10 C53)	National Cancer Statistics Clearing House
6.1	Mortality from cervical cancer (ICD9 180 for data up to and including 1996; ICD10 C53 for data from 1997 onwards)	AIHW Mortality Database
6.2	Mortality by location	AIHW Mortality Database
6.3	Mortality by Indigenous status	AIHW Mortality Database

### Population data

The Australian Bureau of Statistics estimated resident female population has been used to calculate incidence and mortality rates. Participation rates were calculated using the average of the estimated resident female population for the two year reporting period. There may be some variation in published participation rates because national rates use estimated resident population data in the denominator whereas local data analysis may use census counts. The denominator population used to calculate cervical screening participation rates has been adjusted by the estimated proportion of women who have had a hysterectomy by age. These data were derived from the 2001 National Health Survey, and are tabled in Appendix D.

The age-standardised rates in this publication are calculated using the total estimated 2001 mid-year Australian resident population. Where appropriate, rates are also standardised to the WHO World Standard Population for international comparison. Both the Australian and the WHO World Standard Populations are in Appendix D.

### Indigenous mortality data

Due to the difficulties of Indigenous identification, mortality data used in Indicator 6.3 are based on deaths in Queensland, Western Australia, South Australia and the Northern Territory only.

### Other data limitations

- Hysterectomy fractions are calculated using national data derived from the ABS National Health Survey using aggregate data that does not necessarily reflect variation at the state

or territory level. In this report, data from the 2001 National Health Survey have been used.

- Participation rates will be underestimates to the extent that a small percentage of women choose to opt-off local registers and have been excluded from the statistics in this report.
- The participation numbers for states and territories other than Victoria, Australian Capital Territory and the Australian totals may be overestimated because of double counting of some women in registers. This may be the result of difficulty in identifying state or territory of residence for women in border areas and the inclusion in registers of women resident overseas.
- Participation rates published by state and territory programs may differ from those in this publication because of variation in denominators used.

## Appendix C: Methods

This section describes the methods employed to calculate the estimates presented in the tables in the body of this publication.

### Crude rates

A crude rate is defined as the number of events over a specified period of time (e.g. a year) divided by the total population. For example, a crude cancer incidence rate is similarly defined as the number of new cases of cancer in a specified period of time divided by the population at risk. Crude death rates and cancer incidence rates are expressed in this report as rates per 100,000 population. Crude participation rate is expressed as a percentage.

### Age-specific rates

Age-specific rates are calculated by dividing the number of cases occurring in each specified age group by the corresponding population in the same age group expressed as a percentage or a rate per 1,000 or 100,000 population. This rate may be calculated for particular age and sex groupings, e.g.

$$\begin{aligned} \text{Age-specific} \\ \text{cervical cancer} \\ \text{incidence rate in} \\ \text{females aged 50-54} \\ \text{in the year 2002} &= \frac{\text{New cases aged 50 - 54 years (year 2002)}}{\text{2002 female population aged 50 - 54 years}} \times 100,000 \\ &= \frac{78}{650,212} \times 100,000 \\ &= 10.8 \text{ per } 100,000 \end{aligned}$$

### Age-standardised rates (AS rate)

Rates are adjusted for age to facilitate comparisons between populations that have different age structures, e.g. between youthful and ageing communities. There are two different methods commonly used to adjust for age. In this publication we use direct standardisation in which age-specific rates are multiplied against a constant population (the Australian 2001 Population Standard unless otherwise specified). This effectively removes the influence of age structure on the summary rate that is described as the age-standardised rate. The method may be used for the calculation of participation, incidence and mortality rates. The method used for this calculation comprises three steps.

**Step 1:** Calculate the age-specific rate (as shown above) for each age group.

**Step 2:** Calculate the expected number of cases in each 5-year age group by multiplying the age-specific rates by the corresponding standard population and dividing by the appropriate factor (that is, 100,000 for mortality and incidence rates and 100 for the participation rate).

**Step 3:** Sum the expected number of cases in each group, divide by the total of the standard population and multiply by the appropriate factor (that is, 100,000 for mortality and incidence rates and 100 for the participation rate). This gives the age-standardised rate.

## **Confidence intervals**

Population numbers for incidence, mortality and screening have a natural level of variability for a single year above and below what might be expected in the mean over many years. The percentage variability is small for large population numbers but high for small numbers such as mortality in a young age group. One measure of the likely difference is the standard error, which indicates the extent to which a population number might have varied by chance in only one year of data.

In the 95% confidence interval there are about nineteen chances in twenty that the difference will be less than two standard errors.

The 95% confidence intervals (CIs) in this report were calculated using a method developed by Dobson et al. (1991). This method calculates approximate confidence intervals for a weighted sum of Poisson parameters.

## Appendix D: Population data

Table D1: Australian Standard Population<sup>(a)</sup> and WHO World Standard Population<sup>(b)</sup>

Age group	World Standard Population (W)	Australian 2001 Population Standard (A)
0–4	8.86	1,282,357
5–9	8.69	1,351,664
10–14	8.60	1,353,177
15–19	8.47	1,352,745
20–24	8.22	1,302,412
25–29	7.93	1,407,081
30–34	7.61	1,466,615
35–39	7.15	1,492,204
40–44	6.59	1,479,257
45–49	6.04	1,358,594
50–54	5.37	1,300,777
55–59	4.55	1,008,799
60–64	3.72	822,024
65–69	2.96	682,513
70–74	2.21	638,380
75–79	1.52	519,356
80–84	0.91	330,050
85+	0.63	265,235
<b>Total</b>	<b>100.03</b>	<b>19,413,240</b>

*Sources*

(a) ABS 2002.

(b) Ahmad et al, 2002.

**Table D2: Hysterectomy fractions for women aged 15-80+ years, Australia, 2001**

<b>Age group</b>	<b>% of women who have not had a hysterectomy</b>
18-19	100.0
20-24	100.0
25-29	100.0
30-34	98.9
35-39	95.6
40-44	90.6
45-49	82.5
50-54	76.5
55-59	66.2
60-64	68.9
65-69	66.8
70-74	68.1
75-79	67.9
80+	69.0
<b>Total</b>	<b>85.5</b>

Source: ABS 2002.



## Appendix E: National Cervical Screening Programs contact list

### New South Wales

Ms Jane McQueen  
Acting Cervical Screening Program Manager  
Cancer Institute NSW  
Level 1, Biomedical Building  
Australia Technology Park  
EVERLEIGH NSW 2015  
Phone: +61 2 8374 5700  
Email: jane.mcqueen@cancerinstitute.org.au  
Home page: www.cancerinstitute.org.au

### Western Australia

Ms Gillian Mangan  
Program Manager  
Cervical Cancer Prevention Program  
1st Floor, Eastpoint Plaza  
233 Adelaide Terrace  
PERTH WA 6000  
Phone: +61 8 9237 6920  
Fax: +61 8 9237 6991  
Email: gillian.mangan@health.wa.gov.au

### Victoria

Associate Professor Dorota Gertig  
Head of Registry  
Victorian Cervical Cytology Registry  
PO Box 161  
CARLTON SOUTH VIC 3053

### Tasmania

Ms Gail Raw  
Program Manager  
Dept of Health & Human Services  
GPO Box 125B  
HOBART Tas 7001

Ms Vikki Sinnott  
Manager, Cancer Screening Programs  
Dept of Human Services  
50 Lonsdale Street  
MELBOURNE Vic 3000  
Phone: +61 3 9096 0391  
Fax: +61 3 9096 9165  
Email: vikki.sinnott@dhs.vic.gov.au  
Home page: www.dhs.vic.org.au

Ms Lorraine Wright  
Data Manager  
Phone: +61 3 6216 4305  
Email: lorraine.wright@dhhs.tas.gov.au

### Queensland

Ms Jennifer Muller  
Director  
Cancer Screening Services  
Queensland Health  
PO Box 48  
BRISBANE Qld 4001  
Phone: +61 7 3234 0905  
Fax: +61 7 3235 2629  
Email: jennifer\_muller@health.qld.gov.au

### South Australia

Ms Bernadette Kenny  
Acting Program Manager  
SA Cervical Screening Program  
2nd Floor, Norwich Centre  
55 King William Road  
NORTH ADELAIDE SA 5006  
Phone: +61 8 8226 8182  
Fax: +61 8 8226 8190  
Email: bernadette.kenny@health.sa.gov.au

**Australian Capital Territory**

Ms Helen Sutherland  
Program Manager  
ACT Health  
GPO Box 825  
CANBERRA ACT 2601  
Phone: +61 2 6205 1540  
Fax: +61 2 6205 1394  
Email: helen.sutherland@act.gov.au

Mr Peter Couvee  
Database Manager/Coordinator  
ACT Cervical Cytology Register  
ACT Community Health  
GPO Box 825  
Canberra ACT 2601  
Phone: +61 2 6205 1955  
Fax: +61 2 6205 5035  
Email: peter.couvee@act.gov.au

**Northern Territory**

Ms Chris Tyzack  
Program Coordinator  
Well Women's Cancer Prevention Program  
Territory Health Services  
PO Box 40596  
CASUARINA NT 0810  
Phone: +61 8 8922 6445  
Fax: +61 8 8922 5511  
Email: chris.tyzack@nt.gov.au

Mr Guillermo Enciso  
Data Manager  
Casuarina Health Services Centre  
Territory Health Services  
PO Box 40596  
CASUARINA NT 0810  
Phone: +61 8 8922 6441  
Fax: +61 8 8922 6447 or 6455  
Email: guillermo.enciso@nt.gov.au

**Australian Government Department of Health and Ageing**

Screening Section  
Department of Health and Ageing  
GPO Box 9848  
CANBERRA ACT 2601  
Phone: +61 2 6289 8302  
Fax: 61 2 6289 3688  
Home page: [www.cancerscreening.gov.au](http://www.cancerscreening.gov.au)

## Appendix F: NHMRC guidelines for the management of women with screen-detected abnormalities (valid until 3 July 2006)

This reference sheet is a summary of the NHMRC guidelines for the management of women with screen-detected abnormalities. It is intended to assist medical practitioners to take appropriate action on receipt of Pap smear reports.

Low-grade epithelial abnormalities		
Pap smear report	Investigation	Management
Non-specific minor squamous cell changes/atrophia		Repeat smear at 12-monthly intervals until it reverts to normal.
Minor changes in endocervical cells/ low-grade glandular change	Repeat smear in 6 months using cytobrush and spatula. If low-grade abnormality persists, refer for colposcopy and biopsy if indicated.	If endocervical cell abnormality confirmed, refer to gynaecologist for appropriate treatment.
HPV effect/HPV-associated cell changes	Repeat smear at 6-monthly intervals. If HPV-associated cell changes persist after 12 months, refer for colposcopy.	If HPV confirmed, continue with 6 monthly smears until 2 negative reports are received. Repeat smear annually for 2 years then revert to 2-yearly screening.
Possible CIN 1 ± HPV/possible mild dysplasia	Repeat smear at 6-monthly intervals until 2 successive negative reports are received. If lesion persists for 12 months, refer for colposcopy.	If CIN 1 confirmed, follow either observational or active management program as explained on reverse of sheet.
CIN 1 ± HPV/mild dysplasia	Refer for colposcopy and biopsy if indicated.	If CIN 1 confirmed, follow either observational or active management program as explained on reverse of sheet. If higher grade abnormality diagnosed, see below.

High-grade epithelial abnormalities		
Pap smear report	Investigation	Management
CIN 2 ± HPV/moderate dysplasia	Refer for colposcopy and directed biopsy.	If CIN 2 confirmed, treatment by gynaecologist with appropriate expertise is required.
CIN 3 ± HPV/severe dysplasia	Refer for colposcopy and directed biopsy.	If CIN 3 confirmed, treatment by gynaecologist with appropriate expertise is required.
CIN 3 ± HPV with possible invasion; Endocervical glandular dysplasia; or Adenocarcinoma in situ	Refer to gynaecologist with expertise in colposcopic evaluation of malignancies.	Treatment by gynaecologist with appropriate expertise is required.
Invasive squamous cell carcinoma (SCC) or Adenocarcinoma	Refer to gynaecologist skilled in the management of malignancies, or a specialist unit, for urgent evaluation and management.	Treatment by gynaecologist with appropriate expertise is required.
Inconclusive – abnormal cells highly suggestive but not diagnostic of a high-grade abnormality	Refer for colposcopy and possible biopsy, unless there is an obvious diagnostic difficulty e.g. epithelial atrophy or infection. In this case, treat the problem and repeat the smear.	If high-grade lesion confirmed, treatment by gynaecologist with appropriate expertise is required.

### Management of women with low-grade epithelial abnormalities

A cytological assessment of CIN 1 requires referral for colposcopy and, if indicated, biopsy. There is controversy over the management—**observational** and **active**. Both treatment options should be fully discussed with the woman.

#### Observational management

If the diagnosis of CIN 1 is confirmed and the woman elects not to be treated, cervical smears should be taken at 6-monthly intervals until the abnormality either regresses or progresses. After 2 negative smears at 6-monthly intervals, smears should be taken at yearly intervals. If two consecutive annual smears are normal the woman can revert to 2-yearly screening.

#### Active management

Treatment by an accepted method, either ablative or excisional.

	<b>Management</b>
<b>Pap smear report</b>	
Negative/within normal limits	Repeat smear in 2 years.
Negative/within normal limits and no endocervical cells present	Repeat smear in 2 years.
Negative with inflammation	Repeat smear in 2 years.
<i>Note: Investigate any symptoms that are not readily explained, such as post-coital or intermenstrual bleeding. A negative Pap smear must not be taken as reassurance in these circumstances. Further investigation may involve referral to a gynaecologist.</i>	
Unsatisfactory	Repeat smear in 6–12 weeks, with treatment and where possible correction of any problems beforehand if appropriate.

<b>Post-treatment assessment</b>	After initial post-treatment colposcopic assessment by gynaecologist, repeat smear at 6-monthly intervals for 1 year. Following treatment of a high-grade epithelial abnormality, smears should be repeated yearly thereafter. Following treatment for a low-grade epithelial abnormality, revert to normal 2-yearly screening after 2 consecutive normal smears at yearly intervals.
<b>Special circumstances</b>	
Total hysterectomy for CIN	Annual smears from vaginal vault for 5 years, then revert to 2-yearly smears.
Total hysterectomy for benign causes	No further smears required if previous smears were negative. Baseline smear if reason for hysterectomy and/or previous Pap smear history unknown.
Subtotal hysterectomy for benign causes—cervix present	Continue normal 2-yearly screening.
Abnormality during pregnancy	Refer for colposcopy during 1st trimester to exclude invasive disease. If confirmed high-grade abnormality, repeat colposcopy during mid-trimester to exclude progression. Lesion should be reassessed 8 weeks post-partum.

# Abbreviations

ABS	Australian Bureau of Statistics
ACT	Australian Capital Territory
AHMAC	Australian Health Ministers' Advisory Council
AIHW	Australian Institute of Health and Welfare
ASGC	Australian Standard Geographical Classification (the classification designed by the ABS to define the geography of Australia)
AS rate	Age-standardised rate
AS rate (A)	Age-standardised rate using the Australian Standard Population
AS rate (W)	Age-standardised rate using the (WHO) World Standard Population
CI	Confidence interval
CIN	Cervical intraepithelial neoplasia
HGA	High-grade abnormality
HPV	Human papilloma virus
ICD	International Classification of Diseases
LGA	Low-grade abnormality
n.a.	Not available
NCSCH	National Cancer Statistics Clearing House
NOS	Not otherwise specified
NSW	New South Wales
NT	Northern Territory
Qld	Queensland
SA	South Australia
Tas	Tasmania
Vic	Victoria
WA	Western Australia
WHO	World Health Organization

# Glossary

**Ablative therapy:** the destruction of cells on the surface of the cervix using laser therapy, chemicals or diathermy.

**Adenosquamous:** a mix of adenocarcinoma and squamous cells in the same sample.

**Adenocarcinoma:** a cancer formed from the cells of a gland.

**Adjuvant:** enhancing or administered to enhance the effectiveness of a treatment or substance.

**AS rate:** age-standardised rate. A method of removing the influence of age when comparing populations with different age structures. This is usually necessary because the rates of many diseases vary strongly (usually increasing) with age. The age structures of the different populations are converted to the same 'standard' structure, then the disease rates that would have occurred with that structure are calculated and compared (AIHW 2006).

**Atypia:** the condition of being irregular.

**Basement membrane:** the delicate, non-cellular layer on which an epithelium is seated. The epithelium forms the surface portion of the skin and lines hollow organs and all passages of the respiratory, digestive and genito-urinary systems.

**Benign:** not malignant.

**Cancer (malignant neoplasm):** a large range of diseases, in which some of the body's cells become defective, begin to multiply out of control, can invade and damage the area around them, and can also spread to other parts of the body to cause further damage (AIHW 2006).

**Cancer death:** a death where the underlying cause (see *underlying cause of death*) is indicated as cancer. Persons with cancer who die of other causes are not counted in the death statistics in this publication.

**Cervical cancer:** this term covers all cancers specific to the uterine cervix, including micro-invasive cervical cancer. Types of cervical cancers include squamous cell carcinoma, adenocarcinoma (including mucoepidermoid and adenoid carcinomas), adenosquamous, and other and unspecified carcinomas. The term 'all cervical cancers' denotes all these types of cervical cancer, unless otherwise specified.

**CIN (cervical intraepithelial neoplasia):** squamous cell carcinoma of the cervix is mostly preceded, over a period of years, by a spectrum of asymptomatic abnormalities known as cervical intraepithelial neoplasia (CIN) graded as CIN I (mild dysplasia), CIN II (moderate dysplasia) and CIN III (severe dysplasia and carcinoma-in-situ). CIN usually occurs at least a decade before cervical cancer. If CIN remains untreated, some women will develop cervical cancer and others will progress to invasive cervical cancer, despite treatment (AIHW: Jelfs 1995).

**Cone biopsy:** biopsy in which an inverted cone of tissue is excised, as from the uterine cervix.

**Colposcopy:** a microscopic examination of the lower genital tract with a magnifying instrument called colposcope. This method of conservative evaluation allows the clinician to more accurately assess the cytologic abnormality by focussing on the areas of greatest cellular abnormality and by sampling them with a biopsy to attain diagnosis (NCSP 2004).

**Cryosurgery:** the destruction of tissue using extreme cold.

**Dysplasia:** abnormal development or growth patterns of cells (NCSP 2004).

**Endocervical:** the inside of the uterine cervix or the mucous membrane lining of the cervix.

**Epidemiology:** the study of the patterns and causes of health and disease in populations, and the application of this study to improve health (AIHW 2006).

**Epithelium:** tissue lining the outer layer of a body or lining a cavity (e.g. vagina or mouth) (NCSP 2004).

**Exfoliate:** to break away or remove (shed) cells. In the context of this report it refers to the removal of cells from a person for the purpose of a Pap smear test.

**HGA:** high-grade abnormalities as defined for this report include CIN 1/2, CIN 2, CIN 3 or adenocarcinoma-in-situ.

**Histology:** the microscopic study of the minute structure and composition of tissues.

**Hysterectomy:** refers to the surgical procedure whereby all or part of the uterus is removed.

**Hysterectomy fractions:** the proportion of women who have had their uterus removed by hysterectomy.

**HPV:** Human papilloma virus. The virus that causes genital warts and which is linked in some cases to the development of more serious cervical cell abnormalities (NCSP 2004).

**ICD-10:** International Classification of Disease—a coding system used to identify the primary site of the malignancy. This classification is in its tenth revision.

**Incidence:** the number of new cases (of an illness or event, and so forth) occurring during a given period (AIHW 2006).

**Indigenous Australians:** A person of Aboriginal and/or Torres Strait Islander descent who identifies as an Aboriginal and/or Torres Strait Islander and is accepted as such by the community with which he or she is associated (AIHW 2006).

**Intraepithelial:** the area within the layer of cell tissues forming the epidermis of a body cavity. These cells comprise contiguous cells having minimum intercellular substance (NCSP 2004).

**Invasive cancer:** a tumour whose cells have a tendency to invade healthy or normal tissues.

**LGA:** low-grade abnormalities include atypia, warty atypia (human papilloma virus (HPV) effect), possible CIN, equivocal CIN, CIN 1 or endocervical dysplasia not otherwise specified (NOS).

**Lymph node:** masses of lymphatic tissue, often bean-shaped, that produce lymphocytes and through which lymph filters. These are located throughout the body.

**Malignant:** abnormal changes consistent with cancer.

**Metastasis:** the process by which cancerous cells are transferred from one part of the body to another, for example via the lymphatic system or the bloodstream.

**Micro-invasive squamous cell carcinoma (micro-invasive cancer):** lesion in which the cancer cells have invaded just below the surface of the cervix, but have not developed any potential to spread to other tissues.

**Mortality:** see *cancer death*.

**Neoplasia:** the new and abnormal development of cells that may be harmless or cancerous (malignant) (NCSP 2004).

**New cancer case:** a person who has a new cancer diagnosed for the first time. One person may have more than one cancer and therefore may be counted twice in incidence statistics if

it is decided that the two cancers are not of the same origin. This decision is based on a series of principles set out in more detail in a publication by Jensen et al. (1991).

**Pap smear:** a test prepared for the study of exfoliated cells from the cervix (refer to Appendix A).

**Post-partum:** following childbirth.

**Radiation therapy:** the treatment of disease with any type of radiation, most commonly with ionising radiation, such as X-rays, beta rays and gamma rays.

**Screening:** the performance of tests on apparently well people in order to detect a medical condition at an earlier stage than would otherwise be the case.

**Squamous malignancy:** thin and flat cells, shaped like soft fish scales. They line the outer surface of the cervix (ectocervix). They meet with columnar cells in the squamo-columnar junction. 80–85% of cancers of the cervix arise from squamous cells. Abnormalities associated with squamous cells are most likely abnormalities to be picked by Pap smears (NCSP 2004).

**Stroma:** the supporting framework of an organ.

**The Institute:** The Australian Institute of Health and Welfare.

**Tumour:** an abnormal growth of tissue. Can be 'benign' (not a cancer) or 'malignant' (a cancer) (AIHW 2006).

**Underlying cause of death:** the condition, disease or injury initiating the sequence of events leading directly to death; that is, the primary, chief, main or principal cause (AIHW 2006).



# References

- ABS (Australian Bureau of Statistics) 1993. Estimated resident population by age and sex: Australian states and territories, June 1987 to June 1992. ABS cat. no. 3201.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 2002. National Health Survey: summary of results, Australia 2001. ABS cat. no. 4364.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 1999. Deaths Australia 1998. cat. no. 3302.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 2000. Causes of death 1999. cat. no. 3303.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 2001. Information paper: outcomes of ABS views on remoteness consultation, Australia 2001. cat. no. 1244.0.00.001. Canberra: ABS.
- ABS (Australian Bureau of Statistics) 2002. Australian demographic statistics, September quarter 2002. cat. no. 3101.0. Canberra: ABS.
- ABS (Australian Bureau of Statistics) & AIHW (Australian Institute of Health and Welfare) 2005. The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples, 2005. ABS cat. no. 4704.0. AIHW cat. no. IHW 14. Canberra: ABS.
- Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R & Inoue M 2002. Age standardization of rates: a new WHO standard. GPE Discussion Paper Series No. 31. Geneva: World Health Organization. <[www3/whi.int/whosis/discussion\\_papers/discussion\\_papers.cfm](http://www3/whi.int/whosis/discussion_papers/discussion_papers.cfm)>.
- AIHW (Australian Institute of Health and Welfare) & AACR (Australasian Association of Cancer Registries) 2002. Cancer in Australia 1999. AIHW cat. no. CAN 15. Canberra: AIHW (Cancer Series no. 20).
- AIHW: Jelfs PL 1995. Cervical cancer in Australia. Canberra: AIHW (Cancer Series no. 3).
- AIHW (Australian Institute of Health and Welfare) 2006. Australia's health 2006. AIHW cat. no. AUS 73. Canberra: AIHW.
- DHSH (Commonwealth Department of Human Services and Health) 1994a. Summary of NHMRC guidelines for the management of women with screen-detected abnormalities. Canberra: AGPS.
- DHSH (Commonwealth Department of Human Services and Health) 1994b. Screening to prevent cervical cancer: guidelines for the management of women with screen detected abnormalities. Canberra: AGPS.
- Dobson A, Kuulasmaa K, Eberle E, & Scherer J 1991. Confidence intervals for weighted sums of Poisson parameters. *Statistics in Medicine* 10:457-62.
- Doll R & Smith PG 1982. Comparison between cancer registries: age-standardised rates. In: Waterhouse J, Shanmugaratnam K, Muir C & Powell J (eds). *Cancer incidence in five continents, Volume IV*. Lyons: International Agency for Research on Cancer.
- DPIE (Department of Primary Industries and Energy) & DHSH (Department of Human Services and Health) 1994. Rural, remote and metropolitan areas classification. 1991 Census edition. Canberra: AGPS.

National Cervical Screening Program (NCSP) 2004. Research Report: Survey and Analysis of Current Practice in Cervical Histopathology. Screening Monograph No. 2/2004.

Jensen OM, Parkin DM, Machennan R & Muir C (eds) 1991. Cancer registration: principles and methods. Lyons: International Agency for Research on Cancer.

Marcus AC & Crane LA 1998. A review of cervical cancer screening intervention research: implications for public health programs and future research. *Preventive Medicine* 27:13–31.

Ostor AG & Mulvany N 1996. The pathology of cervical neoplasia. *Current Opinion in Obstetrics and Gynecology* 8:69–73.

Snider JA & Beauvais JE 1998. Pap smear utilization in Canada: estimates after adjusting the eligible population for hysterectomy status. *Chronic Diseases in Canada* 19(1):19–24.